

NEW PROGRAM!

CHICAGO LUNG CANCER UPDATES 2018

CONFERENCE CO-DIRECTORS

Jyoti Patel, MD Everett Vokes, MD

Register at: https://cme.uchicago.edu/CLCU2018

OMNI HOTEL

676 North Michigan Avenue Chicago, IL 60611



CONFERENCE DESCRIPTION

This educational program will inform clinicians on new therapeutic options and medical advances for the treatment of lung cancer that can be implemented in an effort to reduce lung cancer related deaths. It will provide physicians and other healthcare professionals with new information that will improve their competence and ultimately improve patient outcomes. By providing important therapeutic and standard of care developments, this conference will educate oncologists on best practices for treating the disease.

TARGET AUDIENCE

This activity has been designed for physicians and other healthcare professionals interested in the prevention and treatment of lung cancer.

LEARNING OBJECTIVES

At the conclusion of this education activity, participants will be able to:

- Describe the appropriate selection of diagnostic modalities in the workup of a patient with suspected lung cancer;
- Identify how to evaluate patients with malignant airway obstruction, mediastinal/hilar adenopathy, and peripheral lung lesions;
- State the role of surgical resection for the treatment of locally advanced and oligometastatic lung cancer;
- Relate how testing approaches inform clinical decision-making for the treatment of advanced NSCLC in multiple lines of care;
- Discuss novel non-invasive strategies for detection of lung cancer;
- Report key clinical trial findings on the use of immunotherapeutic strategies in locally advanced and advanced NSCLC;
- Explain the application of chemotherapeutic and targeted approaches to NSLC;
- Discuss the side effects associated with new chemotherapeutic agents and their management.

ACCREDITATION AND CREDIT DESIGNATION

The University of Chicago Pritzker School of

Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 7 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit from organizations accredited by the ACCME, please consult your professional licensing board.

LOCATION/ACCOMMODATIONS

The conference will be held at the Omni Chicago Hotel, located at 676 North Michigan Avenue.

The only all-suite luxury accommodations on Michigan Avenue are now even better! Embracing the iconic architecture within Chicago, the redesign highlights historical elements of Louis Sullivan's intricate sketches, the Chicago School's building materials and the whimsy of modern sculptures synonymous with the city.

We are pleased to offer a special discounted rate for conference attendees. **The special rates start at \$235.**

Reservations for the UChicago Chicago Lung Cancer Updates 2018 conference must be received by the hotel no later than November 1, 2018 to guarantee this special rate.

• Call: 312.266.3014 and ask for Amanda Byrd (Amanda.Byrd@omnihotels.com)

CONFERENCE PARKING

Parking is available at the Omni Hotel for \$27 per car up to 12 hours.

The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.

* All rates are subject to state and city taxes. All reservations must be secured via a valid major credit card. Check-in time is 3 pm and check-out time is 12 pm.

CONFERENCE FACULTY

Course Directors

Jyoti Patel, MD

Professor of Medicine University of Chicago

Director of Thoracic Oncology, University of Chicago Medicine

Everett E. Vokes, MD

John E. Ultmann Professor Chairman, Department of

Medicine

Physician-in-Chief, University of Chicago Medicine & Biological

Sciences

University of Chicago Speakers Panel Discussants

Christine Bestvina, MD

Assistant Professor (Hematology/Oncology)

Michael Bishop, MD

Professor (Hematology/ Oncology)

Steven Chmura, MD, PhD

Associate Professor of Radiation and Cellular Oncology

Jessica Donington, MD

Professor of Surgery (Thoracic Surgery)

Thomas Hensing, MD

Clinical Associate Professor (Hematology/Oncology)

Philip Hoffman, MD

Professor of Medicine (Hematology/Oncology)

D. Kyle Hogarth, MD

Associate Professor of Medicine Pulmonary/Critical Care

Heber MacMahon, MB

Professor of Radiology & Chief, Thoracic Radiology

Lauren L. Ritterhouse, MD, PhD

Assistant Professor of Pathology

Co-Director, Division of Genomic & Molecular Pathology

Ralph Weichselbaum, MD D.K. Ludwig Professor of

Radiation and Cellular Oncology Chair, Department of Radiation and Cellular Oncology

Brittany Beach, PA

Physician Assistant

Livia Szeto, RN

Research Nurse Associate

Invited Speakers

Hossein Borghaei, DO, MS

Chief, Division of Thoracic Medical Oncology Associate Professor, Department of Hematology/ Oncology

Fox Chase Cancer Center Temple University

Mary Jo J. Fidler, MD

Associate Professor Medical Oncology Rush Medical Center

Shirish M. Gadgeel, MD

Mary Lou Kennedy Research Professor in Thoracic Oncology Professor, Department of Internal Medicine, Division of Hematology/Oncology University of Michigan

Nisha Mohindra, MD

Assistant Professor of Medicine Hematology & Medical Oncology Northwestern University

DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

CONFERENCE AGENDA

FRIDAY, NOVEMBER 16, 2018

| 7:00 a.m. | PRE-TEST AND REGISTRATION | | | |
|--|--|--|--|--|
| | Session 1: Lung Cancer Immunotherapy, New Challenges/Frontiers | | | |
| 8:00 | Welcome and Introductions Jyoti Patel, MD | | | |
| 8:05 | First-Line Immunotherapy (Single agent, IO Doublets) Shirish M. Gadgeel, MD | | | |
| 8:30 | Immunotherapy in Early Stage and Locally Advanced Disease Everett E. Vokes, MD | | | |
| 8:50 | Managing irAEs Christine Bestvina, MD | | | |
| 9:05 | Panel: Crossfire/Clinical Pearls Drs. Vokes, Bestvina, Patel and Gadgeel | | | |
| 9:35 BREAK | | | | |
| | Session 2: Advances in Multidisciplinary Care of the Lung Cancer Patient | | | |
| 10:00 | Radiology Updates (Nodules, GGOs) Heber MacMahon, MB | | | |
| 10:15 | Pulmonary Updates (Peripheral Nodules, EBUS) D. Kyle Hogarth, MD | | | |
| 10:35 | Surgery in the Era of Immunotherapy Jessica Donington, MD | | | |
| 11:00 | Updates in Radiation Oncology Steven Chmura, MD | | | |
| 11:20 | Evolving Role of Molecular Pathologist Lauren L. Ritterhouse, MD, PhD | | | |
| 11:40 | Panel/Interactive Cases: All Speakers + Jyoti Patel, MD; Livia Szeto, RN; Brittany Beach, PA | | | |
| 12:10 p.m. | LUNCH | | | |
| | Session 3: Mutation-Independent Therapy | | | |
| | | | | |
| 1:00 | First Line for PDL-1 Negative and Non-Oncogene Addicted Lung Cancer Hossein Borghaei, MD | | | |
| 1:00 | | | | |
| | Hossein Borghaei, MD | | | |
| 1:20 | Hossein Borghaei, MD Updates on Antiangiogenic Agents Thomas Hensing, MD | | | |
| 1:20 | Hossein Borghaei, MD Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD | | | |
| 1:20 1:35 1:55 | Hossein Borghaei, MD Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat | | | |
| 1:20 1:35 1:55 2:15 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN | | | |
| 1:20 1:35 1:55 2:15 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN BREAK | | | |
| 1:20 1:35 1:55 2:15 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN BREAK Session 4: Advances in Molecular-Based Therapy Changes in the Landscape of EGFR-TKIs. Front Line and Beyond | | | |
| 1:20 1:35 1:55 2:15 2:45 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN BREAK Session 4: Advances in Molecular-Based Therapy Changes in the Landscape of EGFR-TKIs. Front Line and Beyond Christine Bestvina, MD | | | |
| 1:20 1:35 1:55 2:15 2:45 3:00 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN BREAK Session 4: Advances in Molecular-Based Therapy Changes in the Landscape of EGFR-TKIs. Front Line and Beyond Christine Bestvina, MD Sequencing of ALK Inhibitors Mary Jo Fidler, MD | | | |
| 1:20 1:35 1:55 2:15 2:45 3:00 3:20 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN BREAK Session 4: Advances in Molecular-Based Therapy Changes in the Landscape of EGFR-TKIs. Front Line and Beyond Christine Bestvina, MD Sequencing of ALK Inhibitors Mary Jo Fidler, MD BRAF Positive NSCLC Philip Hoffman, MD | | | |
| 1:20 1:35 1:55 2:15 2:45 3:00 3:20 3:35 3:40 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN BREAK Session 4: Advances in Molecular-Based Therapy Changes in the Landscape of EGFR-TKIs. Front Line and Beyond Christine Bestvina, MD Sequencing of ALK Inhibitors Mary Jo Fidler, MD BRAF Positive NSCLC Philip Hoffman, MD Emerging Targets (ROS1, NTRK, Met, Her2) Nisha Mohindra, MD Panel: Challenging Cases in Oncogene Addicted NSCLC | | | |
| 1:20 1:35 1:55 2:15 2:45 3:00 3:20 3:35 3:40 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN BREAK Session 4: Advances in Molecular-Based Therapy Changes in the Landscape of EGFR-TKIs. Front Line and Beyond Christine Bestvina, MD Sequencing of ALK Inhibitors Mary Jo Fidler, MD BRAF Positive NSCLC Philip Hoffman, MD Emerging Targets (ROS1, NTRK, Met, Her2) Nisha Mohindra, MD Panel: Challenging Cases in Oncogene Addicted NSCLC Panel + Drs. Ritterhouse and Chmura | | | |
| 1:20 1:35 1:55 2:15 2:45 3:00 3:35 3:40 3:55 | Updates on Antiangiogenic Agents Thomas Hensing, MD Treatment of Oligometastatic Disease Ralph Weichselbaum, MD Advances in SCLC Jyoti Patel, MD Panel: How I Treat Panel + Drs. Donington, Chmura and Brittany Beach; Livia Szeto, RN BREAK Session 4: Advances in Molecular-Based Therapy Changes in the Landscape of EGFR-TKIs. Front Line and Beyond Christine Bestvina, MD Sequencing of ALK Inhibitors Mary Jo Fidler, MD BRAF Positive NSCLC Philip Hoffman, MD Emerging Targets (ROS1, NTRK, Met, Her2) Nisha Mohindra, MD Panel: Challenging Cases in Oncogene Addicted NSCLC Panel + Drs. Ritterhouse and Chmura Session 5: Cellular Therapies Michael Bishop, MD | | | |

REGISTRATION INFORMATION

How To Register



ONLINE https://cme.uchicago.edu/CLCU2018 (credit card payment only)

To pay by check, you must mail this registration form with payment to:

| Payment | Fee |
|---------------------|-------|
| Physicians | \$150 |
| Trainees and Nurses | \$30 |
| Payment Total: | \$ |



The University of Chicago Center for Continuing Medical Education c/o Chicago Lung Cancer Updates 2018 5841 S. Maryland Ave., MC 1137 Chicago, IL 60637

Contact Information

| Name | D | egree | | |
|---|--------------------|-------|--|--|
| Specialty | | | | |
| Organization | | | | |
| Preferred Mailing Address | | | | |
| City | State | Zip | | |
| Phone | Fax | | | |
| Email | | | | |
| In Case of Emergency | | | | |
| Please indicate any special needs | | | | |
| Please indicate any special dietary needs | | | | |
| Check enclosed (US funds only), payable to The Univ You must check this box if you do not want your mai exhibitors (if applicable). | | | | |
| Please tell us how you found out about this activity, che | ck all that apply: | | | |
| □ Colleague □ Save the Date □ Brochul □ Journal Ad □ Previous Attendance □ Other □ | | | | |

Cancellation Policy

If you cancel your participation in this conference, your registration fee less a \$25 administrative fee will be refunded when written notification is received by October 15, 2018. No refunds will be made after November 1, 2018.

Accessibility

The University of Chicago is committed to providing equal access appropriate to need and circumstance and complies fully with the legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at 773-702-1056 or via email at cme@bsd.uchicago.edu.

For additional information about this activity, please contact the Center for Continuing Medical Education at 773-702-1056.